以岭药业品牌怎么样 申请店铺

我要投票 以岭药业在中草药行业中的票数:71 更新时间:2025-02-05
以岭药业是哪个国家的品牌?「以岭药业」是 石家庄以岭药业股份有限公司 旗下著名品牌。该品牌发源于河北,由创始人吴相君在2001期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
以岭药业怎么样

国家重点高新技术企业--石家庄以岭药业股份有限公司由中国工程院吴以岭院士创建,在他的领导下,以岭药业始终坚持以科技为先导,以市场为龙头的科技创新发展战略,创立"理论-科研-新药-生产-营销"五位一体的独特运营模式,建立起以中医络病理论创新为指导的新药研发创新技术体系。

在以岭药业的发展历程中,凝聚了一大批科研、管理、生产、营销精英,包括归国专家、外籍专家、博士、硕士及各类高职人才,为河北医科大学培养博士、硕士研究生,被国家人事部批准为博士后科研工作站。

以岭药业以络病理论创新带动中医药产业化,运用现代高新技术研发现代中药、西药、和生物药,研发国家专利新药9个,覆盖心脑血管疾病、感冒呼吸疾病、肿瘤、糖尿病及其并发症等重大疾病领域。通过国家GMP认证的中药生产线、通过欧盟认证的化学制剂生产车间具有年产值达50亿的生产能力。以岭药业为国家创新型企业、中国制药工业50强,以岭商标成为中国驰名商标。

国家科技部前领导曾赞誉五位一体的发展模式为"我国中医药科技成果产业化的创举"。

以岭药业立足国内、接轨国际,在石家庄、北京大兴、密云建立了三个国际标准的科研生产基地,通过了欧盟、新西兰等GMP认证。科研、生产、质检、贸易、管理人才全部具有国际化背景,构建了符合国际药品标准的生产、质控体系。依靠现代高新技术与设备和完善的药品生产质量控制体系,生产高品质中药与西药。产品已经出口到英国、美国、西班牙、韩国、日本、俄罗斯、新西兰等许多国家。

位于北京生物工程与医药产业基地的北京以岭药业,占地210亩,为国家重点高新技术企业,主要生产面向国际市场的植物药、保健品、膳食补充剂。

位于北京密云的北京以岭生物按照欧美GMP标准建设,主要生产面向国际市场的激素、肿瘤类药物和具有自主知识产权的新制剂。

Shijiazhuang Yiling Pharmaceutical Co., Ltd, a national key high-tech enterprise, was founded by Academician Wu Yiling of Chinese Academy of engineering. Under his leadership, Yiling pharmaceutical always adheres to the development strategy of scientific and technological innovation with science and technology as the guide and market as the leader, creates a unique operation mode of "theory research new medicine production marketing" and establishes a theoretical innovation of traditional Chinese medicine collateral disease as the reference New drug R & D innovation technology system. In the development process of Yiling pharmaceutical industry, a large number of scientific research, management, production and marketing elites, including returned experts, foreign experts, doctors, masters and all kinds of higher vocational talents, have been gathered, training doctors and masters for Hebei Medical University, and approved by the Ministry of human resources as post doctoral research workstation. Lingyao promotes the industrialization of traditional Chinese medicine with the innovation of collateral disease theory, develops modern Chinese medicine, western medicine and biological medicine with modern high and new technology, and develops 9 new national patent drugs, covering the major disease fields such as cardio cerebrovascular disease, cold and respiratory disease, tumor, diabetes and its complications. The production line of traditional Chinese medicine certified by national GMP and the chemical production workshop certified by European Union have an annual output value of 5 billion. Take Ling pharmaceutical as a national innovative enterprise and top 50 pharmaceutical industry in China, and take Ling trademark as a well-known trademark in China. Former leaders of the Ministry of science and technology of the people's Republic of China once praised the five in one development mode as "the pioneering work of industrialization of scientific and technological achievements of traditional Chinese medicine". Based on domestic and international standards, Yiling pharmaceutical has established three international standard research and production bases in Shijiazhuang, Beijing Daxing and Miyun, and has passed GMP certification of EU, New Zealand, etc. The talents of scientific research, production, quality inspection, trade and management all have international background, and the production and quality control system in line with international drug standards has been established. Relying on modern high-tech and equipment and perfect quality control system of drug production, we can produce high-quality traditional Chinese medicine and Western medicine. The products have been exported to the United Kingdom, the United States, Spain, South Korea, Japan, Russia, New Zealand and many other countries. Located in Beijing bioengineering and pharmaceutical industry base, Beijing Yiling pharmaceutical, covering an area of 210 mu, is a national key high-tech enterprise, which mainly produces plant medicine, health care products and dietary supplements for the international market. Beijing Yiling biology, located in Miyun, Beijing, is built in accordance with European and American GMP standards. It mainly produces hormones, tumor drugs and new preparations with independent intellectual property rights for the international market.

本文链接: https://brand.waitui.com/887854f10.html 联系电话:0311-87320288

千城特选小程序码

7×24h 快讯

慈星股份:终止筹划购买武汉敏声控股权并配套募资事项,股票明起复牌

36氪获悉,慈星股份公告,公司因筹划发行股份及支付现金购买武汉敏声新技术有限公司控股权并募集配套资金事项,公司股票自2025年1月15日开市时起开始停牌。经交易相关方商讨研究决定终止筹划本次交易事项,公司股票将于2025年2月6日(星期四)开市起复牌。 截至公告日,交易各方未就本次交易具体方案、交易条件达成最终实质性协议。

49分钟前

汇丰控股:昨日耗资约1.76亿港元回购219.76万股公司股份

36氪获悉,汇丰控股公告,公司于2月4日耗资约1.76亿港元回购219.76万股公司股份,每股回购价格79.6港元-80.45港元。

49分钟前

印尼网约车巨头GoTo否认与Grab合并传闻

印尼网约车巨头GoTo当地时间2月4日提交文件,否认同竞争对手Grab的合并传闻。该公司称,“除实施股票回购外,未来12个月内没有任何重大行动计划”。此前有市场消息称,Grab与GoTo最近几周加快协商,认为今年是达成交易的有利时机。两家公司上市后均逐渐朝向取得盈利迈进,但竞争激烈导致价格无法调涨,同时挤压利润空间。据报道,过去几年双方一直在断断续续地协商,合并障碍包括双方之间的分歧,以及两家公司在印尼、新加坡等市场主导地位可能带来的反垄断问题。(界面)

50分钟前

众鑫股份:泰国工厂一车间正式投产,预计2025年完成产量3万吨以上

36氪获悉,众鑫股份公告,公司泰国工厂一车间已顺利安装完毕,并于2025年1月8号开始调试设备并试机生产,2月1日顺利完成试机并正式投产。同时,二车间开始安装设备。公司预计2025年完成产量3万吨以上,2026年完成产量5万吨。此外,公司将根据国际市场的变化情况,决策是否对泰国工厂实施扩产计划。本次试机成功为公司拓展海外业务打下了基础,也验证了新装备的先进性,为今后的装备研发与升级提供了宝贵经验。

50分钟前

杭州银行:2024年净利润169.83亿元,同比增长18.08%

36氪获悉, 杭州银行发布业绩快报,2024年度实现营业收入383.81亿元,同比增长9.61%;归属于上市公司股东的净利润169.83亿元,同比增长18.08%。截至2024年末,公司总资产21125.91亿元,较上年末增长14.73%;贷款总额9374.99亿元,较上年末增长16.16%;存款总额12725.51亿元,较上年末增长21.74%。

50分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询